Anti-tnf Inhibitor Antibody-mediated Blockade Of Drug Efficacy In Rheumatoid Arthritis (Antibody-ra)
Anti-tnf Inhibitor Antibody-mediated Blockade Of Drug Efficacy In Rheumatoid Arthritis (Antibody-ra)
The purpose of this study is to examine the relationship between anti-drug antibodies, serum drug concentrations, and clinical response for rheumatoid arthritis patients being treated with etanercept, adalimumab or infliximab.
cross-sectional Population will be selected through convenience sampling. Patients sequentially visiting the rheumatology clinic for routine care who are receiving etanercept, adalimumab, or infliximab for between 6 and 24 months will be evaluated for eligibility and interest in participation. A maximum of 200 patients per treatment will be enrolled.
Inclusion Criteria:
Exclusion Criteria:
Ciudad Autonoma de Buenos Aires, Buenos Aires C1280AEB, Argentina
Ciudad Autónoma de Buenos Aires / Buenos Aires, Buenos Aires / Argentina C1181ACH, Argentina
San Fernando, Buenos Aires / Argentina 1646, Argentina
Ciudad Autónoma de Buenos Aires / Buenos Aires, Ciudad Autónoma de Buenos Aires / Buenos Aires /Argentina. C1430EGF, Argentina
Ciudad de Buenos Aires / Buenos Aires, Ciudad de Buenos Aires, Buenos Aires, Argentina C1055AAF, Argentina
Godoy Cruz, Mendoza / Argentina M5501AAJ, Argentina
S.M. de Tucumán / Tucumán, S.M. de Tucumán / Tucumán / Argentina. 4000, Argentina
San Juan, San Juan / San Juan / Buenos Aires J5402DIL, Argentina
Santa Fe, Santa Fé / Argentina S3000ASL, Argentina
Sandy Bay, Hobart, Tasmania 7000, Australia